Publications

• Humoral immunity and antibody responses against diphtheria, tetanus, and pneumococcus after immune effector cell therapies: A prospective study. Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ. Vaccines. Accepted Sept 2024.
• TARO: tree-aggregated factor regression for microbiome data integration. Mishra AK, Mahmud I, Lorenzi PL, Jenq RR, Wargo JA, Ajami NR, Peterson CB. Bioinformatics. 2024 May 24. PMID: 38788190.
• Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation in melanoma: Impact of antibiotic preconditioning on microbiome and immunity. Glitza IC, Seo YD, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautum S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunins JG, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Cancer Discov. 2024 Apr 4. PMID: 38588588.
• Third-party fecal transplantation for the treatment of high-risk treatment-naive acute graft-versus-host disease of the lower gastrointestinal tract.
  DeFelipp Z, Damania AV, Kim HT, Chang CC, El-Jawahri A, McAfee SL, Bottoms AJ, Toncheva V, Smith M, Dolaher M, Perry L, White M, Diana B, Conolly S, Bimalangshu RD, Frigault MJ, O'Donnell PV, Spitzer TR, Mansour MK, Weber D, Ajami NJ, Hohmann E, Jenq RR, Chen YB. Blood Advances. 2024 Mar 12. PMID: 38471063.
• A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. Nat Cancer. 2024 Feb 13. PMID: 38351182.
• Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. EBioMedicine. 2023 Dec. PMID: 38040541.
• Dissecting the impact of the gut microbiome on cancer immunotherapy. Jain R, Hadjigeorgiou A, Harkos C, Mishra A, Morad G, Johnson S, Ajami N, Wargo J, Munn L, Stylianopoulos T. Res Sq. 2023 Nov 30. PMID: 38076985.
• Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Colbert LE, El Alam MB, Wang R, Karpinets T, Lo D, Lynn EJ, Harris TA, Elnaggar JH, Yoshida-Court K, Tomasic K, Bronk JK, Sammouri J, Yanamandra AV, Olvera AV, Carlin LG, Sims T, Degado Medrano AY, Cisneros Napravnik T, O'Hara M, Lin D, Abana CO, Li HX, Eifel PJ, Jhingran A, Joyner M, Lin L, Ramondetta LM, Futreal AM, Schmeler KM, Mathew G, Dorta-Estremera S, Zhang J, Wu X, Ajami NJ, Wong M, Taniguchi C, Petrosino JF, Jagannadha Sastry KJ, Okhuysen PC, Martinez SA, Tan L, Mahmud I, Lorenzi PL, Wargo JA, Klopp AH. Cancer Cell. 2023 Nov 13. PMID: 37863066.
• Young-onset rectal cancer: Unique tumoral mirobiome and correlation with response to neoadjuvant therapy. White MG, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Lutter-Berkova Z, Chang GJ, Futreal A, Wargo JA, Ajami NJ, Kopetz S, You YN. Ann Surg. 2023 Oct 1. PMID: 37465976.
  
• Using gut microorganisms to treat cancer. Seo YD, Ajami N, Wargo JA. Nat Med. 2023 Jul 7. doi: 10.1038/s41591-023-02460-7. PMID: 37420098.
• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Lee JJ, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189-0. PMID: 36928818. 
• Serial genotyping of the human papillomavirus in cervical cancer: an insight into virome dynamics during chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2023 Feb 16. doi: 10.1016/j.ijrobp.2023.02.018. PMID: 36801350. Sammouri J, Wong MC Lynn EH, El Alam MB, Lo DK, Lin D, Harris TH, Karpinets TV, Court K, Napravnik TC, Wu X, Zhang J, Klopp AH, Ajami NJ, Colbert LE. 
  
• Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.
  J Exp Med. 2023 Feb 6. doi: 10.1084/jem.20221333. PMID: 36367776. Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Khan MAW, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. 
• Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease.
  Res Sq. 2023 Jan 31. doi: 10.21203/rs.3.rs-2460097/v1. PMID: 36778495. Jenq R, Hayase E, Hayase T, Mukherjee A, Stinson S, Jamal M, Ortega M, Sanchez C, Ahmed S, Karmouch J, Chang C, Flores I, McDaniel L, Brown A, El-Himri R, Chapa V, Tan L, Tran B, Pham D, Halsey T, Jin Y, Tsai W, Prasad R, Glover I, Ajami N, Wargo J, Shelburne S, Okhuysen P, Liu C, Fowler S, Conner M, Peterson C, Rondon G, Molldrem JJ, Champlin R, Shpall E, Lorenzi P, Mehta R, Martens E, Alousi A. 
• Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. 
  Nat Med. 2022 Sep 22; Online ahead of print. doi: 10.1038/s41591-022-01965-2. PubMed PMID: 36138151. Simpson RC, Shanahan ER, Batten M, Reijers ILM, Read M, Silva IP, Versluis JM, Ribeiro R, Angelatos AS, Tan J, Adhikari C, Menzies AM, Saw RPM, Gonzalez M, Shannon KF, Spillane AJ, Velickovic R, Lazar AJ, Damania AV, Mishra AK, Chelvanambi M, Banerjee A, Ajami NJ, Wargo JA, Macia L, Holmes AJ, Wilmott JS, Blank CU, Scolyer RA, Long GV.
• Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
  Neoplasia. 2022 Sep; 31:100813. doi: 10.1016/j.neo.2022.100813. PubMed PMID: 35834946. Michikawa C, Gopalakrishnan V, Harrandah AM, Karpinets TV, Garg RR, Chu RA, Park YP, Chukkapallia SS, Yadlapalli N, Erikson-Carter KC, Gleber-Netto FO, Sayour E, Progulske-Fox A, Chan EKL, Wu X, Zhang J, Jobin C, Wargo JA, Pickering CR, Myers JN, Silver N. 
• Microbiome dynamics during chemoradiotherapy for anal cancer.
  Int J Radiat Oncol Biol Phys. 2022 May 2; S0360-3016(2)00396-0. doi: 10.1016/j.ijrobp.2022.04.037.  PubMed PMID: 35513187. Lin D, El Alam MB, Jaoude JA, Kouzy R, Phan JL, Elnaggar JH, Resendiz B, Delgado Medrano AY, Lynn EJ, Nguyen ND, Noticewala SS, Mathew GG, Holliday EB, Minsky BD, Das P, Morris VK, Eng C, Mezzari MP, Petrosino JF, Ajami NJ, Klopp AH, Taniguchi CM, Colbert LE. 
• Immunotherapy response-associated Akkermansia: canary in a coal mine?
  Trends Immunol. 2022 May; 43(5):337-339. doi: 10.1016/j.it.2022.03.007. PubMed PMID: 35397955. Cascone T, Chelvanambi M, Wargo JA.
• Gut microbes as biomarkers of ICI response - sharpening the focus.
  Nat Rev Clin Oncol. 2022 Apr 21; Online ahead of print. doi: 10.1038/s41571-022-00634-0.  PubMed PMID: 35449306. Bhutiani N, Wargo JA. 
• Glioma and the gut-brain axis: opportunities and future perspectives.
  Neurooncol Adv. 2022 Apr 14; 4(1):vdac054. doi: 10.1093/noajnl/vdac054. PubMed PMID: 35591978. Dono A, Nickles J, Rodrigue-Armendariz AG, McFarland BC, Ajami NJ, Ballester LY, Wargo JA, Esquenazi Y. 
• Targeting the gut and tumor microbiota in cancer. 
  Nat Med. 2022 Apr; 28(4):690-703. doi: 10.1038/s41591-022-01779-2. PubMed PMID: 35440726. Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. 
• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
  Science. 2021 Dec 24; 374(6575):1632-1640. doi: 10.1126/science.aaz7015. Epub 2021 Dec 23. PubMed PMID: 34941392. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JE, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA.
• Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
  Nat Commun. 2021 Aug 19; 12(1):5045. doi: 10.1038/s41467-021-25188-0. PubMed PMID: 34413300; PubMed Central PMCID: PMC8376947. Cascone T, Weissferdt A, Godoy MCB, William WN Jr, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B.
• Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 Aug; 27(8):1432-1441. doi:10.1038/s41591-021-01406-6. Epub 2021 Jul 8. PubMed PMID: 34239137. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA.
• Diversity and composition of gut microbiome of cervical cancer patients: Do results of 16S rRNA sequencing and whole genome sequencing approaches align?. J Microbiol Methods. 2021 Jun;185:106213. doi: 10.1016/j.mimet.2021.106213. Epub 2021 Mar 27. PubMed PMID: 33785357; NIHMSID:NIHMS1702347. Biegert G, El Alam MB, Karpinets T, Wu X, Sims TT, Yoshida-Court K, Lynn EY, Yue J, Medrano AD, Petrosino J, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Klopp AH, Colbert LE.
• Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. Clin Infect Dis. 2021 May 4;72(9):1507-1513. doi: 10.1093/cid/ciaa778. PubMed PMID: 32544947; PubMed Central PMCID: PMC8096257. Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, Savidge TC, Arias CA, Ajami NJ, Shelburne SA, Galloway-Pena JR.
• A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021;16(3):e0247905. doi: 10.1371/journal.pone.0247905. eCollection 2021. PubMed PMID: 33662003; PubMed Central PMCID: PMC7932122. El Alam MB, Sims TT, Kouzy R, Biegert GWG, Jaoude JABI, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE.
• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18. PubMed PMID: 33603241; NIHMSID:NIHMS1709525. Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B.
• Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 Feb 22;4(1):237. doi:10.1038/s42003-021-01741-x. PubMed PMID: 33619320. Sims TT, Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo JA, Colbert LE, Klopp AH.
• Human Biofield Therapy Modulates Tumor Microenvironment and Cancer Stemness in Mouse Lung Carcinoma. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420940398. doi: 10.1177/1534735420940398. PubMed PMID: 32975128; PubMed Central PMCID: PMC7522816. Yang P, Rhea PR, Conway T, Nookala S, Hegde V, Gagea M, Ajami NJ, Harribance SL, Ochoa J, Sastry JK, Cohen L. 
• Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020 Dec 10;. doi: 10.1126/science.abb5920. [Epub ahead of print] PubMed PMID: 33303685, Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B.  
• Gut Microbes' Impact on Oncogenic Drivers: Location Matters. Mol Cell. 2020 Sep 17;79(6):878-880. doi: 10.1016/j.molcel.2020.08.021.PMID: 32946762, White MG, Wargo JA.
• Modulating gut microbes. Science. 2020 Sep 11;369(6509):1302-1303. doi: 10.1126/science.abc3965. PMID: 32913089, Wargo JA. 
• Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6. Epub 2020 Jul 13. PMID: 32661409, Finlay BB, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L.
• Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers,  Curr Oncol Rep. 2020 Jun 24;22(7):74. doi: 10.1007/s11912-020-00913-y.PMID: 32577835, McQuade JL, Ologun GO, Arora R, Wargo JA.
• Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review, Semin Hematol, 2020 Jan; 57(1):13-18. doi: 10.1053/j.seminhematol.2020.05.002. Epub 2020 May 19.PMID: 32690139, Halsey T, Ologun G, Wargo J, Jenq RR.
• The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020 May 29; 368(6494):973-980. doi: 10.1126/science.aay9189.PMID: 32467386, Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R.
• Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 Mar; 65(3):885-896. doi: 10.1007/s10620-020-06111-x.PMID: 32067144, Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA. 
• AI finds microbial signatures in tumours and blood across cancer types. Nature. 2020 Mar; 579(7800):502-503. doi: 10.1038/d41586-020-00637-w. PubMed PMID: 32161344, Ajami NJ, Wargo JA. 

April 21, 2021: The Microbiome in Cancer: Minimizing the Hype and Illuminating the Hope. Selected talk from 2021 AACR Annual Meeting. Wargo JA. 

May 5, 2020: Life in the Time of COVID-19. Oncology Times. Kantarjian H, Welch MA, Kornblau S, DiNardo A, Ajami NJ.

April 13, 2020: Looking for Light at the End of the COVID-19 Tunnel. Baker Institute Blog. Kantarjian H, Welch MA, Ajami NJ. 

April 7, 2020: The Importance of Widespread COVID-19 Testing in Houston and the Texas Medical Center. Baker Institute Blog. Kantarjian H, Ajami NJ, DiNardo A.